Nota: 0 de 5 estrelas
0 notas
Carregando
RS![]()
author
Richard M. Schultz
Richard M Schultz has worked as a cancer researcher, medical writer, and drug development consultant for over 35 years. He has always been interested in novel anticancer therapeutics, recognizing t...ver maisRichard M Schultz has worked as a cancer researcher, medical writer, and drug development consultant for over 35 years. He has always been interested in novel anticancer therapeutics, recognizing the limitations of conventional cancer treatments. He received his B.S. degree in microbiology/immunology from the University of Illinois and advanced training at the University of Illinois and George Washington University. He began his career as a research associate at the University of Illinois School of Veterinary Medicine in Urbana, Illinois studying virus-induced tumors in animals. He next worked as a tumor immunologist at both the Frederick Cancer Research Center, Frederick, Maryland and at the National Cancer Institute, Bethesda,MD on the potential role of immunotherapy in cancer. As a senior research scientist, he established a new program on host defense in cancer at Lilly Research Laboratories, Indianapolis, IN and led critical studies on the development of two blockbuster cancer drugs, Gemzar and Alimta.
Richard has concentrated much of his research on some of the most difficult cancers to treat, including pancreatic carcinoma and mesothelioma. He has led efforts to develop novel strategies that target tumor cells and leave normal healthy cells alone. He has developed several experimental models of human cancer in mice. He is an authority on personalized (targeted) cancer therapy and published a monograph on the subject: Advances in Targeted Cancer Therapy, Progress in Drug Research (R. M. Schultz, Ed.), 2005, Birkhauser Verlag, Basel (Switzerland). He has authored over 150 research papers in scientific books and prestigious journals, including Science and Nature and has presented over 100 lectures at national and international cancer meetings. Richard has written several medical review articles on the status of cancer treatment and on new drug development. He is an active member of the American Association of Cancer Research and has been an associate editor for Clinical Cancer Research.ver menos